ClinOne – a leading provider of Adaptive Experiences in clinical trials – announced it closed a $3 million Series A funding to accelerate the growth of its platform and broaden its reach to serve customers. And this latest funding round which was led by Boulder Ventures with participation from existing investors CU Healthcare Innovation Fund and First Trust Capital Partners will continue to advance ClinOne’s mission to offer flexible engagement solutions for all participants to support their clinical trial journey.
As part of the funding round, Robert Conway will join the ClinOne Board as Executive Chair. And Bob served as the CEO of Array BioPharma, Inc 1999 – 2012. Plus he serves as the Chairman of ARCA, Biopharma and is on the board of directors of Signant Health and Alpine Immune Sciences. He is also a member of Genstar Capital’s Strategic Advisory Board. Bob had previously served as Director of eResearch Technology (Clario), PRA International (acquired by ICON, plc), and Advarra Inc.
ClinOne offers an integrated platform that offers comprehensive support for sites, participants, and caregivers throughout the clinical trial journey. And from its Trial Awareness module for Healthcare Provider engagement to Patient Ride, Consent Management, Communities, and Medication Adherence, its cloud-based, no-code, multi-tenant platform provides an environment for rapid, efficient deployment and use.
KEY QUOTES:
“We are thrilled to partner with Boulder Ventures to expand ClinOne’s reach in offering high-quality, rapidly deployed solutions for clinical trials. Bob and I worked together at eRT, and it will be rewarding to work with him again and leverage his experience. We are proud of the work we are doing in partnership with our clients to make clinical trial participation easier for patients. Earning their collective trust is what we strive to achieve.”
– Andrea Valente, CEO at ClinOne
“The most significant opportunity to improve the clinical trial process is the ‘last mile’ serving sites and patients. ClinOne has built a platform which offers ease of use along with comprehensiveness and efficiency for all stakeholders to meet. Andrea has assembled a team with deep experience to realize these goals.”
– Bob Conway
“As longtime investors in the development of new drugs, ClinOne was a natural fit for Boulder Ventures. Participating in a pharmaceutical clinical trial is an act of conspicuous bravery by Patients. ClinOne makes their participation in clinical trials simple, reliable, and useful, and by offering flexibility, can reach a diverse group of participants. ClinOne plays an important role in making clinical trials experiences better for patients.”
– Kyle Lefkoff, General Partner and Founder of Boulder Ventures
